IO Biotech, Inc. Common Stock (IOBT)
IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary immune modulation platform, referred to as Immuno-Oncology Biotech (IOBT), to design therapies that stimulate the body's immune system to target disease more effectively. Founded to advance personalized and combination immune treatments, IO Biotech aims to improve patient outcomes through its novel therapeutic candidates.
Company News
Over 150 pharmaceutical companies are actively developing 170+ pipeline melanoma drugs, with promising therapies in various clinical trial stages targeting improved treatment outcomes through immunotherapies and targeted treatments.
U.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.